BERYL DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.18 INR | +0.59% |
|
-6.15% | +45.55% |
| Sales 2022 | 146M 1.75M 2.41M | Sales 2023 | 269M 3.22M 4.43M | Capitalization | 61.67M 739K 1.02M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -71.93K -98.89K | Net income 2023 | 7M 83.92K 115K | EV / Sales 2022 | 0.68 x |
| Net Debt 2022 | 46.22M 554K 762K | Net Debt 2023 | 39.68M 476K 654K | EV / Sales 2023 | 0.38 x |
| P/E ratio 2022 |
-8.04
x | P/E ratio 2023 |
8.05
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.55% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.59% | ||
| 1 week | -6.15% | ||
| Current month | +0.59% | ||
| 1 month | +2.06% | ||
| 3 months | +9.72% | ||
| 6 months | +45.55% | ||
| Current year | +45.55% |
1 week
30.70
35.00
1 month
28.7043.38
Current year
22.1244.98
1 year
14.2544.98
3 years
7.5044.98
5 years
3.4744.98
10 years
3.4753.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sanjay B. Sethi
CEO | Chief Executive Officer | 60 | 00-12-11 |
Ashish Baraskar
DFI | Director of Finance/CFO | - | - |
Neha Sharma
CMP | Compliance Officer | - | 14-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sudhir B. Sethi
CHM | Chairman | 64 | - |
Sanjay B. Sethi
CEO | Chief Executive Officer | 60 | 00-12-11 |
Shreya Saraf
BRD | Director/Board Member | - | 19-05-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-01 | 32.18 | +0.59% | 5 535 |
| 24-06-28 | 31.99 | -0.81% | 2,903 |
| 24-06-27 | 32.25 | -2.42% | 5,335 |
| 24-06-26 | 33.05 | -1.23% | 5,311 |
| 24-06-25 | 33.46 | -1.39% | 4,683 |
Delayed Quote Bombay S.E., July 01, 2024 at 06:00 am
More quotes
Beryl Drugs Limited is an India-based pharmaceutical manufacturing company. The Company is principally engaged in the manufacturing of bulk drugs. The Company offers a range of manufacturing options to its product requirements, including small volume injectable in liquid form; small volume injectable in dry powder form; a range of eye and ear drops; intravenous (I.V.) fluids in the poly pack and glass bottles, and a range of veterinary medicines. The Company's manufacturing facility is located in Pithampur, India. The Company is mainly engaged in domestic, institutional and export supply. The Company markets a range of branded, generic pharmaceutical formulations through its nationwide sales and distribution network.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +45.55% | 1.95M | |
| +56.80% | 815B | |
| +43.90% | 641B | |
| -6.79% | 352B | |
| +17.64% | 314B | |
| +9.48% | 303B | |
| +16.08% | 242B | |
| +2.29% | 224B | |
| +13.96% | 218B | |
| +8.02% | 168B |
- Stock Market
- Equities
- BERLDRG6 Stock
